Genmab, H Lundbeck sign antibody development agreement
The agreement allows Lundbeck to gain access to Genmab’s antibody creation and development capabilities, including its fully automated pre-clinical antibody screening and characterisation capabilities and its proprietary stabilised
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.